Negotiate around the ability to detect and manage a change—not a promise that regulation will remain unchanged. The following are analyst-recommended commercial protections, to be drafted by counsel:
| Contract area | Requested protection | Decision owner |
|---|---|---|
| Product and facility identity | Named legal entities, physical sites, formulations and presentations; approval before substitution | Procurement + medical director |
| Regulatory events | Prompt notice of relevant inspections, warnings, licence restrictions, recalls and loss of the stated supply basis | Compliance |
| Evidence access | Access to agreed quality, provenance and legal-basis documentation; process for resolving missing evidence | Procurement + counsel |
| Commitments | Suspension/termination rights and treatment of deposits when the agreed route becomes unavailable | CFO + counsel |
| Patient continuity | Responsibilities for pending prescriptions, unshipped orders, refunds, records and communications | COO + clinical lead |
| Clinical information | Ownership of label updates, dosing-device instructions and safety escalation | Medical director |
| Privacy and billing | Approved data uses, subprocessors, charging triggers and cancellation support | Security + compliance |
What is the recommended 30-day implementation plan?
These are management targets, not regulatory deadlines.
- Days 1–5 — map exposure. Identify every product, physical supplier site, destination state, commercial commitment and patient-facing programme. Separate clinic-owned stock from patient dispensing and facilitated branded access.
- Days 6–15 — close critical evidence gaps. Prioritise shortage-dependent claims, 503A personalisation workflows, 503B starting-material assumptions, vial-discard instructions and marketing claims. Hold new commitments where material eligibility evidence remains unresolved.
- Days 16–30 — test alternatives and exit mechanics. Complete a controlled fulfilment test, verify pharmacy coverage for selected states, test Bridge routing where relevant, and reconcile outstanding orders. Clinical leaders should direct any treatment transition; a purchasing review is not an instruction to interrupt treatment.
For the CFO, compare cost per successfully fulfilled patient-month, explicitly defined as fulfilment rather than clinical success. Report medicine, dispensing, shipping, wastage and internal handling separately, and identify whether each charge is paid by the clinic, patient or insurer.
Explore the table row by row
A working view of the research
Product and facility identity
- Requested protection
- Named legal entities, physical sites, formulations and presentations; approval before substitution
- Decision owner
- Procurement + medical director
Sources cited on this page
See the section’s source register for the research context.
Section sources →